Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Employees

Sector

Biotechnology & Medical Research

More about the company

06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
06/07/23	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
14/06/23	Lysogene CFO Assumes Same Role at Mauna Kea Technologies	MT
29/05/23	Lysogene: placed in liquidation and delisted
29/05/23	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
29/04/23	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
17/04/23	Lysogene: no takeover bid received for biotech company
17/04/23	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
27/03/23	Lysogene: deadline for takeover bids extended
06/02/23	Lysogene: interim CFO confirmed
06/02/23	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
03/02/23	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
25/01/23	Lysogene: company placed in receivership

10/10/23	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
18/09/23	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	AQ
29/04/23	LYSOGENE : Inside Information / News release on accounts, results	PU
07/12/22	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
30/11/22	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU

14/06/23	Mauna Kea Technologies : A suivre aujourd'hui
13/06/23	Mauna Kea Technologies : Côme de La Tour du Pin (ex-Lysogene) nommé Directeur financier
29/05/23	Lysogene : placé en liquidation et retiré de la cote
16/05/23	Lysogène: audience le 23 mai sur une possible liquidation judiciaire
02/05/23	Lysogene : reporte la publication de ses résultats et envisage une liquidation judiciaire

Manager	Title	Age	Since
Karen Pignet-Aiach CEO	Chief Executive Officer	54	09/05/2014
Côme de La Tour du Pin DFI	Director of Finance/CFO	-	01/11/2022
Marie Trad CTO	Chief Tech/Sci/R&D Officer	-	01/02/2022

Director	Title	Age	Since
Karen Pignet-Aiach CHM	Chairman	54	22/05/2019
Peter Lichtlen BRD	Director/Board Member	58	01/04/2018
Carole Deffez BRD	Director/Board Member	-	26/09/2019

LYSOGENE Stock

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

Latest news: LYSOGENE

Press Releases: LYSOGENE

News in other languages: LYSOGENE

Managers and Directors: LYSOGENE

Bio Diagnostics & Testing

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LYSOGENE	-.--%	-.--%	-	-	5.53M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+2.58%	+2.14%	+12.77%	+83.68%	54.55B
LONZA GROUP AG	-0.82%	+0.99%	+10.45%	+102.18%	53.59B
IQVIA HOLDINGS INC.	+2.90%	+1.07%	+28.17%	+57.81%	44.75B
BEONE MEDICINES AG	+2.57%	-3.02%	+18.29%	+100.85%	41.62B
REVOLUTION MEDICINES, INC.	+1.17%	-3.33%	+222.87%	+923.51%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.16%	+45.65%	+104.34%	+91.66%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.34%	-0.42%	+51.82%	+162.53%	42.27B
Weighted average by Cap.	+3.49%	-0.29%	+47.41%	+161.35%